title: Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha.
abstract: We analyzed serum triglyceride (TG) levels in 22 chronic myeloid leukemia (CML) patients treated with interferon-alpha (IFN-alpha). Hypertriglyceridemia was present in one-half of patients at diagnosis, and IFN-alpha treatment was associated with a further increase in 90% of the total group of patients. This increase was maximal during the first months of therapy. Four patients (18%) reached levels higher than 1,000 mg/dl. This is the first report describing this secondary effect in CML patients treated with IFN-alpha.
authors.affiliation: Hematology Department, Hospital de la Princesa, Madrid, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Peñarrubia
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
authors.forename: E
authors.initials: E
authors.lastname: Lavilla
authors.forename: F
authors.initials: F
authors.lastname: Casado
authors.forename: M J
authors.initials: MJ
authors.lastname: Requena
authors.forename: M
authors.initials: M
authors.lastname: Picó
authors.forename: R
authors.initials: R
authors.lastname: Arranz
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández-Rañada
mesh_terms: D000293:Adolescent; D000328:Adult; D016632:Apolipoprotein A-I / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D015228:Hypertriglyceridemia / Q000209:etiology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins